
ãè§£æ¯ãã€ãã«ã¡ã¯ãã³ã®ä»£ããã«ãªãïŒïŒããã©ãã¯ã¯ãã³ããâæ»â以å€ã®å šãŠã®ç æ°ãçãã¹ãŒããŒããŒãã
ã»æ¬èšäºã«ã¯åºåãå«ãŸããŠããŸãã
ã»æåŸã«è§£èª¬åç»ããããŸãð¡ïŒ2026.6.14远èšïŒ
ïŒå¹Žã»ã©åã«ã以äžã®èšäºãæžããŸããã
ä»åã¯ãã®ç¶ç·šãç¹å¥ç·šã
çŽïŒå¹Žéãåãæ¯æ¥é£ã¹ç¶ããŠããããã©ãã¯ã¯ãã³ãã玹ä»ããŸãã
ãã®é©ãã¹ãæ£äœãšãçŸä»£ã ããããç¥ã£ãŠããã¹ãå§åçãªãã¯ãŒã«ã€ããŠãææ°ã®ç§åŠçãšããã³ã¹ãæµ·å€ã®æåç·ã®å»çãããã³ã«ã亀ããŠè§£èª¬ããŸãã
ïŒå 容ãããªããïŒ
1. ãã©ãã¯ã¯ãã³ãšã¯ïŒãã®èµ·æºãšæŽå²
2. ç§åŠã蚌æããé©ç°ã®å¹æå¹èœïŒå æã»å€çšïŒ
3. åœéå»ççµç¹ãIMAïŒæ§FLCCCïŒããããã³ã«ã§ã®äœçœ®ã¥ã
ã ã€ãã«ã¡ã¯ãã³ã®ä»£ããã«ãªãïŒïŒã
â ããããã®ãã©ãã¯ã¯ãã³ â
4. æ¥åžžãžã®åãå ¥ãæ¹ïŒå®çšçãªé£ã¹æ¹ã®äŸ 5éž
5. ç¡çãªãæ¯æ¥ç¶ããããã®3ã€ã®ã³ã
1. ãã©ãã¯ã¯ãã³ãšã¯ïŒãã®èµ·æºãšæŽå²
âïžPRïŒåã®ããããååãæ²èŒããæ¥œå€©ROOMãžã®ãªã³ã¯ã§ãïŒ
ååã®ç±æ¥ãšçç©çç¹åŸŽ
ãã©ãã¯ã¯ãã³ïŒåŠåïŒNigella sativa / ãã²ã©ã»ãµãã£ãïŒã¯ããã³ããŠã²ç§ã¯ãã¿ããœãŠå±ã«å±ããäžå¹Žèã§ãããã¯ãã³ããšããååãã€ããŠããŸãããã«ã¬ãŒã«äœ¿ãã»ãªç§ã®ã¯ãã³ãšã¯å šãç°ãªãæ€ç©ã§ããåŠåã®ãNigellaïŒãã²ã©ïŒãã¯ãã©ãã³èªã§ãé»ãããæå³ãããnigerãã«ç±æ¥ããŠããã颚è¹ã®ãããªæå®ã®äžã«éåžžã«çã£é»ã§ç¡¬ããç¬ç¹ã®éŠæ°ãæã€çš®åïŒãã©ãã¯ã¯ãã³ã·ãŒãïŒã宿ãã®ãç¹åŸŽã§ãã
åç£åœãšçç£å°
åç£å°ã¯å°äžæµ·æ²¿å²žã西ã¢ãžã¢ãåã¢ããªã«ãšãããŠããŸããå€ãããã¹ãã€ã¹ãçè¬ãšããŠéå®ãããçŸåšã§ãã€ã³ãããšãžãããäžæ±ãåãšãŒããããªã©ã§åºãæ œå¹ãããŠããŸãã
ãæ»ä»¥å€ãçãã3000å¹Žã®æŽå²
ãã©ãã¯ã¯ãã³ã®æŽå²ã¯3000幎以äžåã«é¡ããäººé¡æå€ã®æ œå¹æ€ç©ã®äžã€ãšèšãããŠããŸãã
å€ä»£ãšãžããïŒãã¿ã³ã«ãŒã¡ã³çã®å¢ãããçºèŠãããŠãããçã®æ»åŸã®å¥åº·ãå®ãããã®ããå®ãããšããŠåè¬ãããŸããããŸããäžçäžå€§çŸå¥³ã®ã¯ã¬ãªããã©ãçŸå®¹ãšå¥åº·ã®ããã«ãã®ãªã€ã«ãæçšããŠãããšäŒããããŠããŸãã
ã€ã¹ã©ã ã®äŒæ¿ïŒããã£ãŒã¹ïŒïŒé èšè ã ãã³ãããããã©ãã¯ã¯ãã³ã«ã¯ãæ»ãé€ãããããç ãçãåãããããšèšãæ®ãããšããœãŒãã¯æ¥µããŠæåã§ãããäžæ±ã§ã¯ãã«ãã³ãžïŒKalonjiïŒãããç¥çŠãããçš®ïŒHabbat al-BarakahïŒããšåŒã°ããäžèœè¬ãšããŠèŠªããŸããŠããŸããã
2. ç§åŠã蚌æããé©ç°ã®å¹æå¹èœïŒå æã»å€çšïŒ
ãã©ãã¯ã¯ãã³ãããã»ã©ãŸã§ã«äžèœãšãããçç±ã¯ãè¿å¹Žã®è¿ä»£å»åŠã»çååŠã®çºå±ã«ãã£ãŠè§£æããã€ã€ãããŸãããã®äžå¿ã«ããã®ããäž»èŠãªæŽ»æ§æåã§ããããã¢ããã³ïŒThymoquinone / TQïŒãã§ãã
äž»ãªå¹æå¹èœïŒå æã«ããã¢ãããŒãïŒ
匷åãªæççã»æé žåäœçšïŒäœå ã®éå°ãªççãåŒãèµ·ãããµã€ãã«ã€ã³ãæå¶ãã现èã®èåãé žåã¹ãã¬ã¹ãé²ããŸãã
å ç«èª¿ç¯ã»æãŠã€ã«ã¹äœçšïŒå ç«åãé«ããäžæ¹ã§ãå ç«ã®æŽèµ°ïŒãµã€ãã«ã€ã³ã¹ããŒã ïŒãæããåæ¹åã®èª¿ç¯æ©èœãæã£ãŠããŸãã
代è¬ã»å¿è¡ç®¡ç³»ã®æ¹åïŒèšåºè©Šéšã«ãããŠãç©ºè ¹æè¡ç³å€ã®äœäžãHbA1cã®æ¹åãæªçã³ã¬ã¹ãããŒã«ïŒLDLïŒã®æžå°ã確èªãããŠããŸãã
ãæ³šç®ãèãžã®å¡åžïŒå€çšïŒãšã¢ãããŒæ§ç®èçãžã®å¹æ
ãã©ãã¯ã¯ãã³ã·ãŒããªã€ã«ã¯ã飲ãã ãã§ãªããçŽæ¥èã«å¡ããããšã§ãåªãã广ãçºæ®ããããšãåãã£ãŠããŸãã
âïžPRïŒåã®ããããååãæ²èŒããæ¥œå€©ROOMãžã®ãªã³ã¯ã§ãïŒ
è¿å¹Žã®ã·ã¹ãããã£ãã¯ã¬ãã¥ãŒïŒè€æ°ã®èšåºè©Šéšãçµ±åããä¿¡é Œæ§ã®é«ãç ç©¶ïŒã«ãããŠããã©ãã¯ã¯ãã³ã¯ã¢ãããŒæ§ç®èçãæ¹¿ç¹ã也ç¬ãããããªã©ã®ç®èçŸæ£ã«å¯ŸããŠææãªæ¹å广ã瀺ãããšãå ±åãããŠããŸãã
ã¡ã«ããºã ïŒãã¢ããã³ã®åŒ·åãªæççäœçšãšæèäœçšããç®èã®ããªã¢æ©èœããµããŒãããã¢ãããŒç¹æã®çã¿ãèµ€ã¿ãåãããŸããéå»ã®ã©ã³ãã 忝èŒè©Šéšã§ã¯ãäžè¬çãªã¹ããã€ãè»èïŒãã¿ã¡ã¿ãŸã³ïŒãä¿æ¹¿å€ïŒå°¿çŽ è»èïŒãšåçããããã¯ãã以äžã®æ·±å»ãªç®èçã®æ¹å床ãããŒãã®åã ãã§ç€ºããããŒã¿ããããŸãã
â ïž ãå€çšæã®éèŠãªæ³šæç¹ã ãã©ãã¯ã¯ãã³ãªã€ã«ã¯éåžžã«ççæŽ»æ§ã匷ããããäœè³ªã«ãã£ãŠã¯ãã¢ã¬ã«ã®ãŒæ§æ¥è§Šç®èçïŒãã¶ãïŒããåŒãèµ·ããã±ãŒã¹ãè«æã§ãå ±åãããŠããŸããåããŠèã«å¡ãéã¯ãå¿ ãäºã®è ã®å åŽãªã©ã§ãããããã¹ãããè¡ããèã«åããªãå Žåã¯çŽã¡ã«äœ¿çšãäžæ¢ããŠãã ããã
3. åœéå»ççµç¹ãIMAïŒæ§FLCCCïŒããããã³ã«ã§ã®äœçœ®ã¥ã
åããã©ãã¯ã¯ãã³ãç¹ã«éèŠèŠããæ¯æ¥æ¬ ãããæãç¶ããŠããæå€§ã®çç±ãããã§ãã
æ°åã³ãããŠã€ã«ã¹æ²»çãã¯ã¯ãã³ã®è§£æ¯ã»ã¹ãã€ã¯ã¿ã³ãã¯éå®³ã®æ²»çã«ãããŠãäžçæåç·ã§ãããã³ã«ãçºè¡šãç¶ããŠããç±³åœã®å»åž«çµç¹ãFLCCCïŒFront Line COVID-19 Critical Care AllianceïŒãã¯ãçŸåšãIMAïŒIndependent Medical Alliance / ç¬ç«å»çã¢ã©ã€ã¢ã³ã¹ïŒããžãšåç§°ã倿Žããçµç¹ãçºå±ãããŠããŸãã
æäžåº·æå çãã·ãã¢ãã§ããŒãšããŠåç»

ãã®äžççãªå»ççµç¹ã§ããIMAã®ã·ãã¢ãã§ããŒã«ã¯ãæ¥æ¬ã®æäœç ç©¶ã»å ç«å»åŠã®ç¬¬äžäººè ã§ããæäžåº·æå çïŒæ±äº¬çç§å€§åŠåèªææïŒãåç»ãããŠããŸããåœå å€ã®ãããã¯ã©ã¹ã®ç§åŠè ã»å»åž«ãã¡ãã婿š©ã«çžãããªãç¬ç«ãããµã€ãšã³ã¹ã远æ±ããŠããçµç¹ã§ãã
ã€ãã«ã¡ã¯ãã³ã®åŒ·åãªä»£æ¿ã»è£å®éžæè¢ãšããŠã®äœçœ®ã¥ã
IMAïŒæ§FLCCCïŒã®åŸéºçããã³ã¹ãã€ã¯ã¿ã³ãã¯é害åãã®æ²»çãããã³ã«ãI-RECOVERããããããŸã§ã®å ¬åŒã¬ã€ãã©ã€ã³ã«ãããŠãäžå¿çãªåœ¹å²ãæããã®ããåç¥ãã€ãã«ã¡ã¯ãã³ãã§ãã ãããŠããããã®ãããã³ã«å ã§ã€ãã«ã¡ã¯ãã³ãšåãã第äžéžææ²»çïŒFirst Line TherapiesïŒãã®æãŠã€ã«ã¹ïŒå ç«èª¿ç¯æåãšããŠãæç¢ºã«çµã¿èŸŒãŸããŠããå€©ç¶æåããããã©ãã¯ã¯ãã³ïŒNigella SativaïŒãªã®ã§ãã
ãªãã代ããã«ããªãã®ãïŒïŒãã©ãã¯ã¯ãã³ã®äž»æåã§ãããã¢ããã³ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã现èã®ACE2å容äœã«çµåããã®ãé»å®³ããæ§è³ªãç ç©¶ã§ç€ºãããŠããŸããããã¯ã€ãã«ã¡ã¯ãã³ãæã€æãŠã€ã«ã¹ã»ã¹ãã€ã¯é»å®³ã¡ã«ããºã ãšé ·äŒŒããŠããŸãã
ãããã³ã«ã§ã®æšå¥šïŒæ§ã ãªçç±ã§ãã€ãã«ã¡ã¯ãã³ãæã«å ¥ããªãããå ¥æå°é£ã§ããããšããå Žåããããã¯ã€ãã«ã¡ã¯ãã³ã®è§£æ¯å¹æãããã«è£å®ã»æå€§åããããã®ç¬¬äžéžæãšããŠãå ¬åŒã«ãã©ãã¯ã¯ãã³ã®æåãæšå¥šãããŠããŸãã
ãããã³ã«ã«åºã¥ãæšå¥šçšé
æ¥ã ã®äºé²ããããããšããæã®æ²»çã»ã±ã¢ãŸã§ãç®çã®ãã§ãŒãºã«åãããŠä»¥äžã®çšéãäžççãªææšãšãªã£ãŠããŸãã
äºé²ç®çïŒæ§FLCCCå ¬åŒåæ¬ããïŒïŒ40 mg/kg/day ïŒã€ãã«ã¡ã¯ãã³ãæã«å ¥ããªãå Žåã®ä»£æ¿ããŸãã¯äºé²å¹æãæå€§åããããã®äœµçšæåãšããŠå ¬åŒæå®ïŒ
æ²»çã»åŸéºçã±ã¢ç®çïŒIMAãããã³ã«ããïŒïŒ80 mg/kg/day ïŒãã¡ãŒã¹ãã©ã€ã³ã®æãŠã€ã«ã¹ïŒå ç«èª¿ç¯æåãšããŠå ¬åŒæå®ïŒ
ãå ·äœäŸïŒäœé60kgã®äººã®å Žåã äœé60kgã®æ¹ã§ããã°ã1æ¥ãããçŽ2.4gïŒäºé²æïŒã 4.8gïŒæ²»çã»ã±ã¢æïŒãæšå¥šéãšãªããŸãã ãã©ãã¯ã¯ãã³ã·ãŒãã¯å°ãã1æ¯ã§ããã3.3gã§ãã®ã§ãæç®ãããšã1æ¥ã«ãããå°ãã1æ¯åŒ±ã1æ¯åçšåºŠãã®éãç®å®ã§ãããã®ç¯å²ã®äžã§ããèªèº«ã®äœèª¿ãç®çã«åãããŠæåéã調æŽããŠã¿ãŠãã ããã
ð¡ ããããã®ãã©ãã¯ã¯ãã³
éžãã ã¢ã€ãã ãåã®æ¥œå€©ã«ãŒã ã«ãŸãšããŠããŸãã çšéã奜ã¿ã«åãããŠã䜿ãããããã®ãéžãã§ã¿ãŠãã ããã
以äžã®ç޹ä»ãªã³ã¯ã«ã¯åºåïŒPRïŒãå«ãŸããŸãã
ð ãã·ãŒãïŒçš®ïŒãæ¯æ¥ã®æçãçŽè±ã«ãµãããããªããã
ð ããªã€ã«ããããããšåããããããèã®ã±ã¢ã«äœ¿ããªãããïŒâ»èŠããããã¹ãïŒ
ð ããµããªã¡ã³ããç¬ç¹ã®èŠã¿ã颚å³ãèŠæãªæ¹ã»æè»œã«æã¡éã³ãããªããã
4. æ¥åžžãžã®åãå ¥ãæ¹ïŒå®çšçãªé£ã¹æ¹ã®äŸ 5éž
ãã©ãã¯ã¯ãã³ã¯ãå°ãããªããšããèŸã¿ãšãã»ãèŠãããããŠããŒãã®ãããªã¹ãŒããšããç¬ç¹ã®é¢šå³ãæã£ãŠããŸããããã§ã¯ãåãæ®æ®µãããªã¢ã«ã«å®è·µããŠããæ¹æ³ãšãããããªé£ã¹æ¹ããããããšããããããã®ã¢ã¬ã³ãžãåãããŠ5ã€ç޹ä»ããŸãã
ãåãå®éã«ãã£ãŠããæ¹æ³ã
â ãçŽè±ã«æ··ããïŒãµããããïŒãïŒæ¯æ¥æ¬ ãããªãåã®ããŒã¹
ãããåã®ããŒã¹ã§ãããæãããããã®ã«ãŒãã£ã³ã§ããæ¯æ¥ã®çŽè±ã«ããã©ãã¯ã¯ãã³ã·ãŒãããã®ãŸãŸæ··ããŠé£ã¹ãŸããçŽè±ã®åŒ·ãæšå³ãšçºé µã®é¢šå³ããããã¯ã¿ã¬ããã©ãã¯ã¯ãã³ã®çãããŸãå ã¿èŸŒãã§å³ã«æ·±ã¿ãåºãŸããæè»œã«æ¯æ¥ç¶ããããåãªãã®æ¹æ³ã§ããïŒãªã€ã«ãæ··ããŠããããããïŒ
â¡ ããã³ã«ãããããšäžç·ã«ããããïŒãšãã©ããããŸã
ããŸã«ããŠãããæ°ã«å ¥ãã®é£ã¹æ¹ã§ããããŒã¹ããããã³ã«çããããïŒéå ç±ïŒããã£ã·ãå¡ãããã®äžãããã©ãã¯ã¯ãã³ããããŸããããããã®æ¿åãªçããšãã©ãã¯ã¯ãã³ã®ã¹ãã€ã·ãŒãªã»ãèŠããçµ¶åŠã«ãããããé«çŽæã®ãã倧人ãªå³ããã«ãªããŸãããã£ã¡ãããŸãã
â¢ ãæ¯æ¥ã®ã¹ãŒããã«ã¬ãŒã®ä»äžãã«ãïŒã¹ãã€ã¹æèŠã§
åºæ¥äžãã£ãã«ã¬ãŒãããå³åæ±ãã³ã³ãœã¡ã¹ãŒããªã©ã®ä»äžããšããŠé©éå ããŸããç¹ã«ã«ã¬ãŒãšã®çžæ§ã¯æçŸ€ã§ãïŒå ç±ãããããšæå¹æåãæžå°ããå¯èœæ§ããããããç«ãæ¢ããåŸãé£ã¹ãçŽåã«å ¥ããã®ãã³ãã§ãïŒã
ããããªé£ã¹æ¹ãããããïŒã
⣠ããšãŒã°ã«ããã¢ãµã€ãŒããŠã«ã«ãããã³ã°ã
æé£ã®ãšãŒã°ã«ãã«ããã©ãã©ãšæ¯ããããæ¹æ³ã§ããã奜ã¿ã§ã°ã©ããŒã©ãããããªã©ãå ãããšãã¹ãã€ã¹ã®ã¢ã¯ã»ã³ãããã¶ãŒãæèŠã§çŸå³ããããã ããŸãã
†ãæã®å¥åº·ã¹ã ãŒãžãŒã«ãã¬ã³ãã
ãããããªã³ãŽããããã€ã³ãªã©ããããµãŒã«ãããéãäžç·ã«æå ¥ããŠæªæããŸãããã«ãŒãã®åŒ·ã颚å³ã«ããæ¶ããããããç¬ç¹ã®å³ãã©ãããŠãèŠæãªæ¹ã§ãå šãæ°ã«ãªããã«æåã§ããŸãã
5. ç¡çãªãæ¯æ¥ç¶ããããã®3ã€ã®ã³ã
çŽ2幎éãåãïŒã»ãŒïŒ1æ¥ãæ¬ ããããã©ãã¯ã¯ãã³ãç¶ããããŠããã®ã¯ã以äžã®ãä»çµã¿ããäœã£ãããã§ãã
ã³ã1ïŒæ¯æ¥é£ã¹ããåºå®ã®äž»é£ããšã»ããã«ãããåã®å Žåã¯ãæ¯æ¥ã®çŽè±ãã«æ··ããããšãå®å šã«åºå®åããŠããŸãããäœãé£ã¹ãæã«äœ¿ãããããšãã®éœåºŠè¿·ããšãã«ã®ãŒããªããããšããç¿æ £åã®äžçªã®è¿éã§ãã
ã³ã2ïŒåäžã«ããã«ãåžžã«çœ®ããŠãããå¡©è¡æ€ã®ããã«ãé£åã«ãã©ãã¯ã¯ãã³ã·ãŒããå ¥ããã¹ãã€ã¹ããã«ãåžžåããŠãããŸããããã«ãããå€é£ã®èæçããµã©ãã«ããšããããäžæ¯ããããã®ãç¡æèã«ã§ããããã«ãªããŸãã
ã³ã3ïŒè€æ°ã®åœ¢ç¶ïŒã·ãŒãã»ãªã€ã«ã»ãµããªïŒã䜿ãåãããæçã®é£æãæãã¿ããæã¯ãã·ãŒããããããããèã±ã¢ïŒâ»èŠããããã¹ãïŒã«ã¯ããªã€ã«ããå¿ããæãå³ããã€ããšæããæ¥ã¯ããµããªã¡ã³ãããšãã£ãããã«ãç¶æ³ã«åãããŠäœ¿ãåãããšé£œããæ¥ãŸããã
â ïž å 責äºé ã»æåã«ã€ããŠã®ãé¡ã
æ¬èšäºã§ç޹ä»ããŠããæ å ±ã¯ãåŠè¡è«æãåœéå»ççµç¹ã®ãããã³ã«ãåºã«ããäžè¬çãªå¥åº·æ å ±ã§ãããç¹å®ã®å»çè¡çºãæ²»çãæšå¥šãããã®ã§ã¯ãããŸããããã©ãã¯ã¯ãã³ïŒå æã»å€çšïŒã®æåã䜿çšã«ããã£ãŠã¯ããèªèº«ã®äœè³ªãæç ããè¬ãšã®é£²ã¿åãããªã©ãèæ ®ãããèªèº«ã®å€æãšèªå·±è²¬ä»»ã«ãŠãé¡ãããããŸããç¹ã«ãèãžäœ¿çšãããéã¯ãäºåã®ããããã¹ããå¿ ã宿œããŠãã ããã
è³æäžèЧ
æ¬èšäºã®å·çã«ããããåŒçšã»åèã«ããåŠè¡è«æããã³å ¬çæ©é¢ã®è³æäžèЧã§ãã
åŠè¡è«æïŒPubMed / PMCïŒ
The Therapeutic Effects of Nigella sativa on Skin Disease: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsïŒã¢ãããŒæ§ç®èçãå«ãç®èçŸæ£ãžã®å¹æã«é¢ããã·ã¹ãããã£ãã¯ã¬ãã¥ãŒã»ã¡ã¿ã¢ããªã·ã¹
Black Seeds (Nigella sativa) Medical Application and Pharmaceutical PerspectivesïŒãã©ãã¯ã¯ãã³ã®å»çå¿çšã«é¢ããç·åã¬ãã¥ãŒ
åœéå»ççµç¹ãããã³ã«
IMAå ¬åŒãããã³ã«ïŒæ²»ççšéã80 mg/kg dailyãã®èšè¿°ãã
FLCCCå ¬åŒãããã³ã«ïŒç±³æ¿åºå ¬çã¢ãŒã«ã€ãïŒïŒäºé²çšéã40 mg/kg dailyãã®èšè¿°ãã
ãKojiGenbaã ããããã¢ã€ãã ã®çŸå ŽïŒ
å¥åº·ã¢ã€ãã äžå¿ã«å€æ°ç޹ä»äžâŒïžïŒæ¥œå€©ROOMïŒ
远èšïŒ2026.6.14ïŒ
解説åç»ãã€ãããŸããð¡
- #å¥åº·
- #ç¿æ £
- #æ°åã³ãããŠã€ã«ã¹
- #解説
- #ãªãŒã¬ããã¯
- #ã¢ãããŒ
- #ãããã¯ã¹
- #ãµããªã¡ã³ã
- #æ°åã³ããã¯ã¯ãã³
- #å ç«åã¢ãã
- #ãªã€ã«
- #ã·ã§ãã£ã³ã°
- #ã¹ãŒããŒããŒã
- #è§£æ¯
- #ã€ãã«ã¡ã¯ãã³
- #ã·ãŒã
- #ã¹ãã€ã¯ã¿ã³ãã¯
- #ãã²ã©
- #IMA
- #æäžåº·æ
- #ãã©ãã¯ã¯ãã³
- #FLCCC
- #ãã¢ããã³
- #SSSN